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Abstract
Background: In vivo studies demonstrate that the Prox1 transcription factor plays a critical role in the development of 
the early lymphatic system. Upon Prox1 expression, early lymphatic endothelial cells differentiate from the cardinal vein 
and begin to express lymphatic markers such as VEGFR-3, LYVE-1 and Podoplanin. Subsequent in vitro studies have 
found that differentiated vascular endothelial cells can be reprogrammed by Prox1 to express a lymphatic gene profile, 
suggesting that Prox1 can initiate the expression of a unique gene signature during lymphangiogenesis. While the in 
vitro data suggest that gene reprogramming occurs upon Prox1 expression, it is not clear if this is a direct result of Prox1 
in vascular endothelial cells in vivo.
Results: Overexpression of Prox1 in vascular endothelial cells during embryonic development results in the 
reprogramming of genes to that of a more lymphatic signature. Consequent to this overexpression, embryos suffer 
from gross edema that results in embryonic lethality at E13.5. Furthermore, hemorrhaging and anemia is apparent 
along with clear defects in lymph sac development. Alterations in junctional proteins resulting in an increase in 
vascular permeability upon Prox1 overexpression may contribute to the complications found during embryonic 
development.
Conclusion: We present a novel mouse model that addresses the importance of Prox1 in early embryonic 
lymphangiogenesis. It is clear that there needs to be a measured pattern of expression of Prox1 during embryonic 
development. Furthermore, Prox1 reprograms vascular endothelial cells in vivo by creating a molecular signature to 
that of a lymphatic endothelial cell.
Background
The specialization of the vasculature is driven by a num-
ber of molecular pathways that dictate the fate of blood
vessels to that of an artery or vein [1]. Following this ini-
tial programming, the development of the lymphatic sys-
tem is dependent on the further differentiation of the
venous endothelium. The newly differentiated lymphatic
endothelial cells migrate in a polarized fashion to
coalesce into an early lymph sac, which then progress to
form the lymphatic vasculature proper [2,3].
A number of genes have been found to be associated
with the lymphatic endothelial cell profile, for example
LYVE-1, Podoplanin and VEGFR-3 [4-6]. In addition to
this profile, the transcription factor Prox1 has been found
to act as an important regulatory switch, altering the
molecular identity of venous endothelium and imparting
them with attributes that augment lymphatic develop-
ment. Indeed, genetic ablation of prox1 results in embry-
onic lethality; hemizygous null mice are found to die
shortly after birth [3]. In both cases, a major developmen-
tal defect was found to involve the emerging lymphatic
system. Specifically, the early lymphatic endothelial cells
(LECs) that normally bud off from the cardinal vein (CV)
in a polarized manner do not do so. Instead, prox1 null
LECs do not migrate, resulting in defective lymph sac for-
mation and consequently no development of a functional
lymphatic system. Furthermore, these null cells molecu-
larly default to a more vascular-like phenotype. To this
end, prox1 null mice display lymphedema and chylous
ascites buildup resulting in death [2,3].
* Correspondence: dan.dumont@sri.utoronto.ca
1 Sunnybrook Research Institute University of Toronto 2075 Bayview Avenue 
Toronto, Ontario, M4N 3M5, Canada
Full list of author information is available at the end of the article© 2010 Kim et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Kim et al. BMC Developmental Biology 2010, 10:72
http://www.biomedcentral.com/1471-213X/10/72
Page 2 of 10It is clear that vascular endothelial cells require the reg-
ulated expression of Prox1 early in development, initiat-
ing a transcriptional program that results in lymphatic
differentiation. This point underscores the plasticity of
differentiated endothelial cells under the influence of
Prox1. Indeed, microarray analysis of vascular endothelial
cells engineered to overexpress Prox1 resulted in the
upregulation of lymphatic specific genes while downreg-
ulating a number of blood specific genes [7,8]; this study
extending the known surface markers of lymphatic
endothelial cells by providing a more in-depth character-
ization of LEC gene signature. The in vivo knockout data
demonstrates that prox1 plays an important role in early
lymphatic development. Furthermore, targeted deletion
of prox1 within vascular endothelial cells recapitulates
the lymphatic defect and the edematous phenotype [9].
Moreover, in vitro studies suggest that this lymphatic
defect is potentially due to an inability to molecularly
reprogram early vascular endothelial cells to a lymphatic
fate [7,8]. Given this however, it is not clear whether the
reprogramming to a specific gene signature does indeed
occur in vivo. Here we describe an in vivo model to
address the molecular significance of Prox1 in repro-
gramming vascular endothelial cells to that of a lymphatic
gene profile.
Results
Prox1 expression in double transgenic mice
In order to investigate whether Prox1 is necessary and
sufficient in regulating cell fate, we have generated a
mouse model that forces the expression of Prox1 specifi-
cally in vascular endothelial cells. Our transgenic model
takes advantage of a bigenic expression system driven by
the tie1 promoter (Figure 1a). This model results in tar-
geted expression within vascular compartments such as
the cardinal vein as well as the dorsal aorta (Figure 1b and
1c, see Additional file 1). While the expression of Prox1 in
DT embryos is also found on both arteries and veins,
both these vascular structures appear to differentially
overexpress Prox-1 throughout development in our
model suggesting that arterial and venous endothelial
cells may regulate Prox-1 RNA/protein levels in a differ-
ent fashion. While the directionality of the budding lym-
phatic endothelial cells appear to be more tightly
regulated in control embryos, DT embryos appear to dis-
play more Prox1 positive cells in the periphery. These
results suggest that normally, Prox1 expression and lym-
phatic endothelial cell budding are tightly controlled and
can be disrupted by the overexpression of Prox1 in the
developing vasculature.
Phenotype of DT Prox1 mice
As development progresses, both the vascular and lym-
phatic system matures to form two separate yet critically
interrelated circuits. In early development, there are no
overt deficiencies in the blood vasculature of DT
embryos. However, by E10.5 we begin to observe small
hemorrhages on the surface of developing DT embryos
(Figure 2a and 2b, arrorwheads). At later stages in devel-
opment we notice some subtle delays in growth, more
profound blood loss, with blood pooling within the
embryo (Figure 2c and 2d). In the most severe embryonic
cases we find anemic embryos that display massive
edema at E13.5 where the epidermis separates from the
body as a result of trapped extravasated fluid (Figure 2e
and 2f, double arrowhead). Upon further analysis, DT
embryos that harbor the most severe phenotypes also
display enlarged lymph sacs relative to their control coun-
terparts (Figure 2e and 2f). These results suggest that the
overexpression of Prox1 can pose a developmental crisis
during early gestation. Indeed, 33% of postnatal DT's do
not make the expected Mendelian double transgenic ratio
(Table 1). However, the majority of the postnatal DT's do
appear to survive to birth. These results suggest that the
overexpression of Prox1 can have deleterious conse-
quences in the developing embryo correlating with hem-
orrhaging, anemia and edema.
Figure 1 Bigenic model for Prox1 overexpression. (A) The 
prox1:tetOS transgene is driven by the tissue specific tie1:tTA promoter. 
Open circle: tTA, closed circle: Prox1 protein. (B) The expression of 
Prox1 in E10.5 embryos displays a polarized expression pattern specif-
ically from the cardinal vein. (C) In contrast, overexpression of Prox1 in 
the double transgenic (DT) embryos display an increase in Prox1 posi-
tive cells from the cardinal vein. Significantly, Prox1 is also present on 
the dorsal aorta, which is normally negative for Prox1 expression. Ori-
entation arrows for B and C: D- Dorsal, L- Lateral. Scale bar: 50 μm.
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Given the influence of Prox1 on gene regulation in vascu-
lar and lymphatic endothelial cells, we further investi-
gated the possibility of a switch in the molecular identity
of endothelial cells using markers that are influenced by
Prox1. To this end, we started our analysis with the yolk
sac, a relatively simple tissue that is rich in blood vascula-
ture (Figure 3a). Analysis of control or DT embryos reveal
that the overexpression of Prox1 in vascular endothelial
cells could alter gene expression to that of a more lym-
phatic endothelial cell signature. For example, transcripts
for genes such as VEGFR-3 and CyclinE2 increase while
VEGFR-2, Neuropilin1 and Stat6 decrease (Figure 3b).
Furthermore, protein levels from yolk sacs derived from
DT embryos demonstrate that VEGFR-2 and Tie2
decrease while Neuropilin-2 increases with a marginal
increase in VEGFR-3. Wholemount analysis of DT yolk
sacs support the reprogramming event, indicated with an
increase in Podoplanin expression that correlates with
Prox1 overexpression (data not shown). Consistent with
previous findings, the overexpression of Prox1 in vascular
endothelial cells appear to sufficiently alter the gene sig-
nature of BECs to that of a more LEC profile in vivo.
Jugular veins from Prox1 DT embryos display lymphatic 
markers
To visualize the potential of Prox1 in reprogramming the
vascular endothelium, markers such as VEGFR-3 and
Podoplanin were used to analyze the developing jugular
vein (JV). Within the DT samples, it was found that the
levels of VEGFR-3 increased relative to that observed in
the control embryos (Figure 4a versus b, arrows). Previ-
ous studies by Schacht et al. show that Podoplanin
expression is tightly regulated during development, being
expressed early on the JV and gradually being downregu-
lated by E13.5. This downregulation coincides with a shift
in expression to the developing lymph sacs derived from
the same JV [5]. Interestingly, at the timepoint where
Podoplanin expression should be downregulated on the
jugular vein, DT embryos show strong expression of
Podoplanin relative to controls (Figure 4c versus d,
arrows). These results further suggest that the overex-
pression of Prox1 can alter the expression pattern of vas-
Table 1: Analysis of number of embryos and postnatal births.
E10.5
+/+
70
Prox1/+
58
Tie1/+
65
Tie1/Prox1
46
Total
239
DT observed*19.2%
DT expected 25%
Ratio of observed:absent**(%) 76:24
E12.5
+/+
83
Prox1/+
34
Tie1/+
52
Tie1/Prox1
29
Total
198
DT observed 14.6%
DT expected 25%
Ratio of observed:absent (%) 58:42
E13.5
+/+
35
Prox1/+
9
Tie1/+
29
Tie1/Prox1
9
Total
82
DT observed 10.9%
DT expected 25%
Ratio of observed:absent (%) 44:56
Postnatal
+/+
68
Prox1/+
54
Tie1/+
57
Tie1/Prox1
36
Total
215
DT observed 16.7%
DT expected 25%
Ratio of observed:absent (%) 67:33
* DT observed % is calculated as the number of DT animals/Total number of animals × 100%.
** Observed % is calculated as the DT observed %/DT expected% = percentage of animals observed for that Mendelian ratio × 100%. Absent % is 
calculated as 100-observed%
A catalogue of the total number of embryos and live births from each genotype at various developmental timepoints. Also shown is the 
percentage of DT births observed and expected, with the % ratio of observed births versus the percentage presumed to be lethal. Total of 519 
embryos were assessed and 215 postnatal births observed.
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signature.
Overexpression of Prox1 correlates with changes in 
junctional proteins in vivo and in vitro
With the overexpression of Prox1, changes in gene signa-
tures are observed in the developing embryo. These
changes correlate with defects in embryonic development
such as edema and hemorrhaging. While it suggests that
the overexpression of Prox1 in the early developing vas-
culature is causal to these defects, the functional explana-
tion for the edema and hemorrhaging is unclear. One
possibility that may explain the observed developmental
defects may lie in changes in vessel permeability upon
Prox1 overexpression. To investigate this possibility, pro-
teins that are associated with tight junctions were ana-
lyzed from yolk sacs of control and DT embryos.
Interestingly, the overexpression of Prox1 results in the
alteration of junctional proteins from the normal pattern
of expression such as ZO-1, Occludin and to a lesser
extent JAM-1 (Figure 5a). Further analysis using cultured
venous endothelial cells [10] show that overexpression of
Prox1 results in a similar trend of misregulated junctional
targets such as ZO-1 and PECAM-1 (Figure 5b), these
changes correlating with an altered cellular morphology
(Figure 5c). To further define the consequences of Prox1
overexpression in VECs, an in vitro permeability assay via
Boyden chamber was performed comparing control
VECs with those that overexpress Prox1. Significantly,
VECs that overexpress Prox1 display a higher degree of
permeability, assessed by the passage of FITC-albumin,
when compared to control VECs (Figure 5d). This sug-
gests that VECs become more permeable with Prox1
overexpression, potentially due to alterations in the integ-
rity of cell-cell junctions.
Discussion
The importance of Prox1 in initializing differentiation
was shown to be a result of its ability to reprogram blood
endothelial cells to a lymphatic endothelial cell profile.
This molecular switch shown in vitro suggested that
Prox1 initiates the transcriptional machinery necessary
for lymphangiogenesis [8,11]. While the Prox1 knockout
study as well as a tissue specific deletion of Prox1 in the
endothelium [9] point to the necessity of Prox1 in lym-
phatic development, it does not provide a complete
extension on the molecular players that confer the ability
to reprogram the blood vasculature as suggested from in
vitro studies [7,8]. To this end, one way to address this
involves the specific overexpression of Prox1 in the
endothelial cell compartment. In the present study, we
examine the importance of vascular reprogramming and
fate specificity in vivo with a tie1/prox1 bigenic mouse
model that specifically expresses Prox1 in early vascular
endothelial cells.
Early expression of Prox1 in vascular endothelial cells
result in no overt embryonic phenotype, however as
development progresses Prox1 double transgenic
embryos appear growth delayed and display more overt
bleeding. Of the most serious cases, DT embryos are ane-
mic and edematous. This correlated with the alteration of
a number of molecular targets associated with vascular
reprogramming such as an increase in VEGFR-3, Neuro-
pilin-2 and STAT6 and a decrease in Neuropilin-1,
VEGFR-2, Tie-2 and CyclinE2 [7,8,12]. Examination of
the most severely affected DT embryos show a general
degradation of the embryonic structure, separation of the
epidermis and enlarged lymph sacs when compared to
their wild type counterparts. Furthermore, vascular
structures such as the jugular vein, which normally
express low levels of VEGFR-3 and Podoplanin are now
highly positive for these lymphatic markers. In conjunc-
tion with previous data demonstrating the importance of
Prox1 in BEC differentiation to LECs, we present data
that provides further in vivo evidence of the molecular
players involved in the reprogramming of BECs to LECs
early in lymphatic vascular development. Consistent with
our data, it was recently observed that Sox18 is upstream
of Prox1; in vitro overexpression of Sox18 in embryonic
stem cells and vascular endothelial cells results in the
upregulation of Prox1 and an increase in lymphatic mark-
ers such as Podoplanin, indirectly confirming our data
presented here [13]. In addition, the conditional deletion
of Prox1 results in the dedifferentiation of lymphatic
endothelial cells to that of a more vascular endothelial
cell-like phenotype [14]. This further suggests that Prox1
is critical for the maintenance of the lymphatic endothe-
lial cell fate, and that endothelial cells are genetically mal-
leable. Our in vivo study further confirms the importance
of Prox1 in generating a lymphatic profile by altering the
gene signature of vascular endothelial cells.
One consequence that results from the overexpression
of Prox1 in the vascular compartment of the developing
embryo is edema. At the histological level, we observe the
separation of the dermal layer from the epidermis as a
result of fluid leakage, characteristic of an improper lym-
phatic drainage system. Furthermore, a prominent fea-
ture of the most severely affected embryos is the
enlargement of the lymph sacs. It is unclear as to the
mechanism of the increased size, whether it is from an
increase in the number of differentiating early lymphatic
endothelial cells budding from the jugular vein, or from
an increase in proliferation of committed lymphatic
endothelial cells that are in the process of or have already
formed the lymph sac. Interestingly, early analysis of
E10.5 DT embryos show an increase in Prox1 positive
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play a contributing factor to the increase in lymph sac
size. The potential for an increase in proliferation due to
Prox1 overexpression is consistent with previously pub-
lished work that identifies the upregulation of a number
of cell cycle targets such as CyclinE2 and p57kip [7].
The data suggests that the overexpression of Prox1 dur-
ing early embryogenesis results in the reprogramming of
vascular endothelial cells to a more lymphatic cell fate
resulting in edema, hemorrhaging and death. While it
demonstrates the importance of tightly regulating Prox1
in development, it is unclear as to why the hemorrhaging
Figure 2 Overexpression of Prox1 results in embryonic lethality at E13.5. Control and DT embryos were analyzed at (A and B) E10.5 and (C and 
D) E12.5. Interestingly, overexpression of Prox1 results in a small amount of hemorrhaging and growth retardation (B; arrowheads). Later time points 
display exacerbated bleeding with a consistent delay in growth (C and D). (E and F) Histological analysis at E13.5, embryos display gross edema typified 
by separation of the dermis from the epidermis (F; double arrow). Also significant is the increase in lymph sac size (LS) in Prox1 transgenic embryos. 
LS: Lymph sac. Orientation arrows for E and F: D- Dorsal, L- Lateral. Scale bars for A and B: 5.0 mm; C and D: 1.0 cm; E: 250 μm and F: 500 μm.
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expression of Prox1 may influence junctional proteins
involved in maintaining the integrity of cell-cell contacts;
alterations in these same complexes may result in changes
in vascular permeability leading to a more permeable,
lymphatic-like state [15]. Indeed, upon Prox1 overepres-
sion changes in junctional proteins are observed away
from the normal molecular profile associated with con-
trol embryos. Previous studies have shown that increases
as well as decreases in junction protein levels have been
shown to be associated with an increase in permeability
[16,17], suggesting that a balance is required in order to
maintain the integrity of the cell-cell interface. Recent
data has found that the overexpression of Prox1 in colon
epithelial cells result in dysplasia and transformation that
correlates with changes in cellular adhesion [11]. Further-
more, conditional deletion of Prox1 results in aberrant
junctional complex formation and abnormal pericyte
association [14]. These lines of evidence point to the
importance of cell-cell integrity in the regulation of vas-
cular permeability. Moreover, the controlled expression
of Prox1 is critical for normal lymphatic development in
the embryo.
It is clear that the measured expression of Prox1 as well
as other lymphangiogenic factors during embryonic
development is essential for the proper formation of the
lymphatic vasculature. Not surprisingly, compromising
this regulated expression has been found to result in neg-
ative clinical consequences. For example, the growth of
lymphatic endothelium in tumors is a result of the pres-
ence of VEGF-C, which acts on lymph vessels to enhance
metastasis [18]. Other events include the transformation
and cellular reprogramming of spindle-like lesional cells
by Karposi sarcoma herpesvirus (KHSV)/human herpes-
virus-8 (HHV8). Interestingly, gene profiling of KHSV
infected lesional cells produce a signature similar to that
derived from a lymphatic endothelial cell; targets that
include Prox1, LYVE-1 and VEGFR-3. This suggests that
Karposi sarcoma genetically mimics an expression pat-
tern similar to a differentiated lymphatic endothelial cell
[19-21].
Conclusions
In conclusion, we extend the previous in vitro studies that
characterized the molecular profile of reprogrammed
vascular endothelial cells that overexpress the Prox1 tran-
scription factor. Furthermore, we also demonstrate that
the tight regulation of Prox1 is critical for normal embry-
onic lymphatic development. While the expression pat-
tern of Prox1 in our model does not fully recapitulate the
GFP expression found in the Tie1-GFP mouse model, it is
clear that when Prox1 is overexpressed in our tissue spe-
cific model it results in aberrant lymph sac development,
hemorrhaging, edema, anemia and ultimately, embryonic
lethality. In a corresponding study, Johnson et al. demon-
strated that Prox1 was essential for the maintenance of
the lymphatic phenotype, where a global temporal dele-
tion of Prox1 during mid-development effectively depro-
grams lymphatic structures to that of a vascular
endothelial-like phenotype, assessed by surface markers
such as Podoplanin and SLC [14]. Our data presented
here complement the work by Johnston et al., whereby
the tissue specific overexpression of Prox1 reprograms
similar markers to a more lymphatic-like profile. Further-
more, we elucidate some of the molecular components
that accompany vascular endothelial cell reprogramming
involved in early lymphatic differentiation and develop-
ment. The development of our unique model comple-
ments and extends the current viewpoint of Prox1 being
an important initiator of lymphatic development via its
ability to reprogram endothelial cells to a specific molec-
ular profile.
Figure 3 Analysis of reprogramming in yolk sacs from Prox1 dou-
ble transgenic embryos. (A) Analysis of control and DT embryos at 
E10.5 (lanes 1 and 2) and yolk sacs at E10.5 or E12.5 (lanes 3 to 6) for 
prox1 expression by RT-PCR. (B) Yolk sacs from E13.5 control and DT 
embryos were analyzed using RT-PCR for the expression of lymphatic 
associated markers such as CyclinE2, Stat6, VEGFR-2, VEGFR-3 and Neu-
ropilin-1 (NRP1). -ve represents no template control. (C) Similarly, yolk 
sacs from E12.5 control and DT embryos were analyzed by western 
blot for the expression of VEGFR-2, VEGFR-3, Tie2 and Neuropilin-2 
(NRP2).
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Generation of mice
The Animal Care and Ethics Committee approved all ani-
mals and protocols that were used. The construction of
the tie1 and tie2 tTA driver transgene has been previously
described [22]. The prox1 cDNA was inserted into the
pTetOS responder construct and transgenic animals were
derived at the McGill Transgenic Facility, Montreal, Que-
bec, Canada. Driver and responder transgenic animals
were bred to generate bigenic embryos. Embryos were
genotyped and wild type, single and double transgenics in
the presence of doxycycline was used as controls relative
to double transgenics without doxycycline. Doxycycline
treatment involved the addition of 100 μg/mL of doxycy-
cline/5% sucrose in the drinking water and changed at
least twice per week.
Immunofluorescence and immunohistochemistry
Embryos were prepared by fixing in 4% paraformaldy-
hyde, followed by incubation in 30% sucrose and
mounted in OCT for cryosectioning. Sections were
treated with 0.5% TritonX-100/PBS and blocked in
5%BSA/10%goat serum prior to antibody incubation.
Antibodies used were anti-Prox1 (102PA30, RDI), Podo-
planin (clone 8.1.1) and VEGFR-3 (16-5988, eBiosci-
ences). Immunohistochemistry was counterstained with
Harris hematoxylin.
RT-PCR analysis
Yolk sacs were placed in Trizol (GibcoBRL) and pro-
cessed following manufacturers protocol. In brief, tissues
were homogenized and 200 μL of chloroform was added
per 1 mL Trizol. Following centrifugation at 10,000 × g
for 15 minutes at 4°C, the upper phase was removed and
300 μL of 100% ethanol was added per 1 mL of Trizol.
After 5 minutes incubation at room temperature, RNA
was isolated by centrifugation at 2,000 × g for 5 minutes
at 4°C. Proteins were then precipitated from the phenol-
ethanol supernatant by 1.5 mL isopropyl alcohol per 1 mL
Trizol. After 10 minutes incubation at room temperature,
protein precipitate was isolated at 12,000 × g for 10 min-
utes at 4°C. Reverse transcriptase was performed as per
Figure 4 Immunohistochemistry of Prox1 embryos for lymphatic markers. E13.5 embryos were analyzed for the markers VEGFR-3 and Podopla-
nin on the jugular vein (JV) of control and double transgenic Prox1 embryos. (A) In control samples VEGFR-3 expression is relatively low in comparison 
to (B) Prox1 DT embryos (arrows). (C) In control embryos, Podoplanin is found expressed on the jugular vein during early development, however it 
begins to be downregulated and moves to the lymph sac (LS). (D) In contrast, overexpression of Prox1 results in the sustained expression of Podopl-
anin on the jugular vein (JV; arrowheads) as well as the enlarged lymph sac (LS). Scale bar: 100 μm.
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Figure 5 Overexpression of Prox1 results in changes in junctional proteins in vivo and in vitro. (A) RT-PCR analysis was performed on yolk sacs 
derived from E13.5 embryos to targets such as ZO-1, Occludin and JAM-1. (B) Similarly, in vitro analysis shows that overexpresion of Prox1 in vascular 
endothelial cells decreases junctional protein levels. (C) Bright field microscopy of VECs transfected with Prox1 (10x mag) (D) Vascular endothelial cells 
that overexpress Prox1 display an increase in permeability measured by FITC-albumin transit in a Boyden chamber assay. Figure is representative of 
three experiments with all samples run in triplicate. Error bars represent standard deviation of the mean. P < 0.05.
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sents no template. PCR primers used were as follows:
mVEGFR-2 For: ATGAAATTGAGCTATCTGCC, Rev:
CCACTGGATGTGGTGCAGGG
mNeuropilin-1For: GCAATAGCAAAAGAAGGTTT,
Rev: ACCATGCCCAACAATCCAGA
mStat6 For: ATCCAGCTTCAGGCCCTGTC, Rev:
TCTATCTGTGAGGAGCCATC
mCyclinE2 For: ATCCAGTCTACAGATTCCGA, Rev:
ATCCAGTCTACAGATTCCGA
Prox1 For: ATGCCTGACCATGACAGC, Rev:
GGGAAGCTTTTGCTTGCG
mJAM-1 For: CCGAGTGGAGTGGAAGTTCGTCC,
Rev: AGGAACGACGAGGTCTGTTTGAATTC
mOccludin For: ACTTCAGGCAGCCTCGGTACAG,
Rev: CTCCCGCAACTGGCATCTCTCTAA
mZO-1For: TCACAGGGCTCCTGGGTTTGGAT,
Rev: CTAGTGACTGAATTTCTGAAATGTCATCT
GAPDH For: CTGCACCACCAACTGCTTAG, Rev:
TCTCATCATACTTGGCAGGT
Western analysis
Venous endothelial cells used in this study have been pre-
viously characterized [10]. Proteins were lysed in RIPA
buffer for 30 minutes on ice (10 mM NaH2PO4 pH7.5, 150
mM NaCl, 1% NP-40, 0.1% SDS, 1% Sodium Deoxy-
cholate, 10 mM NaF, 2 mM EDTA, Protease Inhibitor
cocktail (Complete-EDTA free, Roche USA), and 10 mM
sodium orthovanadate, cleared by centrifugation and the
supernatants collected for further analysis. Equal
amounts of lysates were resuspended with 2xSDS loading
buffer and separated via SDS-PAGE. Proteins were trans-
ferred to PVDF, blocked with 3% milk/tris buffered saline,
incubated with the appropriate primary and secondary
antibody conjugated to horse radish peroxidase, and
developed via enhanced chemiluminescence (Pierce).
Antibodies used include Prox-1 (07-537, Upstate), CD31
(557355, BD Biosciences), ZO-1 (40-2300, Zymed) and β-
actin (AC15, Sigma).
Permeability assay
This protocol is a modification of the permeability assay
by Chemicon (ECM640). To generate Prox1 overexpress-
ing cells, bovine VECs [10] were transfected with a
human Prox1 cDNA via Lipofectamine 2000 as per man-
ufacturers protocol (Gibco). 2 × 105 cells were plated in a
3 μm pore size transwell with no substrate. Positive con-
trols included 100 ng/mL of VEGF-A/25 mM EDTA in
the top well. Also included in the top well was 250 μg/mL
of FITC-Albumin to quantitate permeability through the
cell monolayer. After the cells were incubated for 48
hours, passage of FITC-Albumin (250 μg/mL) into the
bottom chamber was detected at an excitation/emission
ratio of 488/530. n = 3, performed in triplicate.
Statistical analysis
Data was presented as standard errors from the mean.
Statistical significance was taken at P < 0.05 using an
unpaired, two-tailed Student's t-test.
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